Osteoboost Health, a California-based medical technology company, has officially launched Osteoboost, a prescription wearable device, across the US.
This medical device is claimed to be the first US Food and Drug Administration (FDA)-cleared solution specifically designed for individuals with low bone density, addressing a significant gap in treatment options for over 60 million Americans.
With the aging population increasingly focused on maintaining bone health as part of an active lifestyle, Osteoboost seeks to mitigate fracture risks that threaten mobility and independence.
Osteoboost is engineered for easy at-home use, integrating advanced consumer technology with medical innovation. The device focuses on delivering targeted vibration therapy to the spine and hips, the anatomical regions most vulnerable to osteoporotic fractures.
Osteoboost Health CEO Laura Yecies said: “The longevity conversation is everywhere, but people rarely mention bone health even though it is fundamental to aging with confidence.
“Osteoboost empowers people to lead longer, stronger, and more active lives. And while the belt is sophisticated medical technology rigorously tested and validated for efficacy, the treatment is so easy – 30 minutes a day of gentle vibration therapy that can be done while walking, cooking, or other daily activities.”
The FDA has classified Osteoboost as a Class II De Novo device and designated it a breakthrough device. Its patented vibration technology underwent rigorous evaluation in a gold-standard clinical trial, confirming its ability to significantly slow the decline in vertebral bone density and strength.
A clinical trial at the University of Nebraska Medical Center revealed that Osteoboost achieves an 85% reduction in spinal bone density loss, an 83% reduction in spinal bone strength loss, and a 55% reduction in hip bone density loss.
These results were observed in postmenopausal women with osteopenia using the device three times per week.
To broaden accessibility, Osteoboost Health has partnered with Beluga Health to provide online prescription consultations. This collaboration allows patients to obtain prescriptions either through their personal physicians or via online services, facilitating quicker access to new treatment options.
The initiative is bolstered by recent investments from AARP, Harvard Business School Angels, and Esplanade Ventures, supporting the device’s widespread deployment and adoption.
